Amoxicillin Shortage: A Provider's Update for 2026

Amoxicillin remains one of the most frequently prescribed antibiotics in outpatient settings, yet its supply has been disrupted repeatedly since 2022. This guide provides clinicians with the latest supply status, evidence-based alternative recommendations, and practical strategies for managing patient access in 2026.

Current Supply Status

The Amoxicillin supply landscape has improved materially since the acute shortages of 2022-2024:

• Oral suspension: The FDA resolved the Amoxicillin powder for oral suspension shortage on May 2, 2025. Pediatric liquid formulations are broadly available, though localized stock-outs may persist during peak respiratory season.
• Capsules (500 mg): ASHP reported back orders for 500 mg capsules in 50-count and 500-count bottles from select manufacturers, with estimated release dates in early January and February 2026 respectively. Most bottle sizes have since returned to normal distribution.
• Tablets and chewable tablets: No significant supply disruption reported.

The FDA has documented seven shortage events for Amoxicillin, underscoring its vulnerability to supply chain disruptions. Providers should maintain awareness of current availability through the ASHP Drug Shortage Resource Center and the FDA Drug Shortage Database.

Root Cause Analysis

The recurring Amoxicillin shortages stem from structural vulnerabilities in the generic antibiotic supply chain:

• Concentrated manufacturing: A limited number of manufacturers produce the majority of U.S. Amoxicillin supply, creating single points of failure.
• Offshore raw material sourcing: Active pharmaceutical ingredient (API) production is concentrated overseas, introducing geopolitical and logistical risk.
• Demand volatility: Respiratory season demand can exceed baseline by 30-50%, and manufacturers of low-margin generics lack incentive to maintain large safety stock.
• Formulation complexity: Oral suspensions require specialized manufacturing capabilities, and fewer facilities produce them compared to solid oral dosage forms.

Notably, the FDA approved USAntibiotics of Bristol, Tennessee under the National Priority Voucher Pilot Program — the first approval under this initiative — to bolster domestic Amoxicillin manufacturing and reduce supply chain fragility.

Therapeutic Alternatives: Evidence-Based Guidance

When Amoxicillin is unavailable, the following alternatives are supported by clinical guidelines. The optimal choice depends on the indication, patient allergies, local resistance patterns, and formulary considerations.

Acute Otitis Media (AOM)

• First-line alternative: Amoxicillin/Clavulanate (high-dose: 90 mg/kg/day amoxicillin component)
• Second-line: Cefdinir 14 mg/kg/day, Cefuroxime axetil 30 mg/kg/day, or Ceftriaxone 50 mg IM x 3 days
• Penicillin allergy: Azithromycin 10 mg/kg day 1, then 5 mg/kg days 2-5

Acute Bacterial Sinusitis

• First-line alternative: Amoxicillin/Clavulanate 875/125 mg BID (adults) or 45 mg/kg/day (pediatric)
• Second-line: Doxycycline 100 mg BID (adults), Levofloxacin 500 mg daily (adults, reserve for refractory cases)
• Penicillin allergy: Azithromycin or Trimethoprim-Sulfamethoxazole (regional resistance rates permitting)

Group A Streptococcal Pharyngitis

• First-line alternative: Penicillin V 500 mg BID-TID x 10 days (adults), 250 mg BID-TID (pediatric)
• Second-line: Cephalexin 500 mg BID x 10 days, Cefadroxil 1 g daily x 10 days
• Penicillin allergy: Azithromycin 500 mg day 1, then 250 mg days 2-5; Clindamycin 300 mg TID x 10 days

Community-Acquired Pneumonia (CAP)

• Outpatient, no comorbidities: Doxycycline 100 mg BID, or Azithromycin 500 mg day 1 then 250 mg days 2-5 (if local resistance <25%)
• Outpatient, with comorbidities: Amoxicillin/Clavulanate 875/125 mg BID + macrolide, or respiratory fluoroquinolone monotherapy

Urinary Tract Infections

• Amoxicillin is generally not recommended as empiric UTI therapy due to high E. coli resistance rates. Preferred alternatives: Nitrofurantoin, Trimethoprim-Sulfamethoxazole, or Fosfomycin per IDSA guidelines.

Prescribing Strategies During Supply Disruption

1. Verify availability before prescribing: Direct patients to check pharmacy stock using tools like Medfinder for Providers or call ahead.
2. Specify dosage form flexibility: When clinically appropriate, indicate on the prescription that alternative dosage forms (capsules, tablets, suspension) are acceptable at equivalent doses.
3. Leverage telehealth for rapid follow-up: If a patient reports inability to fill, a brief telehealth encounter can facilitate a timely switch to an available alternative.
4. Coordinate with pharmacy: Pharmacists can often identify available stock across chain locations and facilitate prescription transfers.
5. Avoid inappropriate prescribing: Antibiotic stewardship remains critical. Prescribing Amoxicillin for viral infections (or prescribing "just in case" during shortages) exacerbates both resistance and supply problems.

Patient Communication Guidance

Patients are understandably concerned when they cannot fill a prescribed antibiotic. Consider sharing these resources:

• Patient-facing shortage update
• How to find Amoxicillin in stock
• Alternatives to Amoxicillin for patients

For provider-specific tools and resources, visit medfinder.com/providers.

Looking Ahead

With new domestic manufacturing capacity from the FDA's priority voucher program and improved supply chain monitoring, Amoxicillin availability is expected to remain more stable going forward. However, vigilance is warranted — particularly during respiratory season peaks.

Providers should also be familiar with how to help patients find Amoxicillin in stock and how to help patients save on Amoxicillin costs.